多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗:规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
双靶向最终应在大规模 III 期试验中,与靶点转换的单靶向药物序贯治疗这一经典方案进行比较。
ALL SOURCES
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
双靶向最终应在大规模 III 期试验中,与靶点转换的单靶向药物序贯治疗这一经典方案进行比较。
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
多发性骨髓瘤是一种血液系统恶性肿瘤,其特征是复杂的遗传和微环境因素驱动疾病进展和治疗耐药。
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
这些结果提示,双特异性抗体可作为复发/难治性多发性骨髓瘤(RRMM)患者 CAR-T 细胞治疗后复发的标准治疗。
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
抗BCMA BsAb疗效有限,而非BCMA BsAb可能在ide-cel早期复发后提供一种有前景的治疗方法。
Integrating Immune Therapies for the Treatment of Multiple Myeloma.
对蛋白酶体抑制剂、免疫调节剂(IMiD)和抗 CD38 抗体均难治的复发/难治性多发性骨髓瘤(RRMM)患者(三类难治性 MM)预后较差。
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
分析了 44 个队列(2 个一线队列和 42 个复发/难治性队列)的 52 篇报告,共纳入 1833 例患者。
The evolution of bispecific antibodies in multiple myeloma.
多发性骨髓瘤(MM)的治疗在过去十年中发生了革命性变化,随着靶向CD38的单克隆抗体如达雷妥尤单抗和伊沙妥昔单抗的问世,这些药物已被整合到新诊断或复发和/或难治性(R/R)MM患者的治疗武器库中。
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
对于适合移植、延迟移植以及适合但不适合移植且年龄小于80岁的患者,我们使用基于抗CD38单克隆抗体、来那度胺和硼替佐米/卡非佐米的四联方案作为诱导方案。
SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.
早期复发多发性骨髓瘤的治疗应个体化,以优化患者结局,并在可接受的毒性特征下实现长期缓解。
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.
多发性骨髓瘤(MM)是一种骨髓浆细胞癌症。
MEMBER ACCOUNT
登录成功会直接打开下一页。